Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 20/20 | 0.84 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19451509 | 1.00 | STING1 (0.84) | STING1CYP3A4TBK1 | |
| SCHEMBL28413370 | 1.00 | STING1 (0.84) | STING1CYP3A4TBK1 | |
| SCHEMBL29586400 | 1.00 | STING1 (0.84) | STING1CYP3A4TBK1 | |
| SCHEMBL25074339 | 0.97 | STING1 (0.80) | STING1CYP3A4TBK1 | |
| SCHEMBL20066383 | 0.96 | STING1 (0.81) | STING1CYP3A4TBK1 | |
| SCHEMBL23227988 | 0.96 | STING1 (0.78) | STING1CYP3A4TBK1 | |
| SCHEMBL19451711 | 0.96 | STING1 (0.78) | STING1CYP3A4TBK1 | |
| SCHEMBL19451513 | 0.96 | STING1 (0.80) | STING1CYP3A4TBK1 | |
| SCHEMBL20066425 | 0.95 | STING1 (0.75) | STING1CYP3A4TBK1 | |
| SCHEMBL20066435 | 0.94 | STING1 (0.75) | STING1CYP3A4TBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4346894-A1 | ADJUVANTS | GlaxoSmithKline Biologicals S.A. (BE) | 2024-04-10 | — | — | EP | claimed |
| WO-2022248353-A1 | ADJUVANTS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2022-12-01 | — | — | WO | claimed |
| WO-2025029832-A2 | STING AGONIST COMPOUNDS AND CONJUGATES | SUTRO BIOPHARMA, INC. (US) | 2025-02-06 | — | — | WO | disclosed |
| EP-4419100-A1 | ADJUVANT COMPOSITION COMPRISING STING AGONISTS | GlaxoSmithKline Biologicals S.A. (BE) | 2024-08-28 | — | — | EP | disclosed |
| CN-118215475-A | Adjuvant compositions comprising STING agonists | 葛兰素史克生物有限公司 | 2024-06-18 | — | — | CN | disclosed |
| EP-4346894-A1 | ADJUVANTS | GlaxoSmithKline Biologicals S.A. (BE) | 2024-04-10 | — | — | EP | disclosed |
| WO-2023066872-A1 | ADJUVANT COMPOSITION COMPRISING STING AGONISTS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023020992-A1 | NOVEL METHODS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-02-23 | — | — | WO | disclosed |
| WO-2023020994-A1 | NOVEL METHODS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-02-23 | — | — | WO | disclosed |
| WO-2023020993-A1 | NOVEL METHODS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-02-23 | — | — | WO | disclosed |
| WO-2022248353-A1 | ADJUVANTS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2022-12-01 | — | — | WO | disclosed |
| EP-4032885-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2022-07-27 | — | — | EP | disclosed |
| EP-3440076-B1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2022-06-01 | — | — | EP | disclosed |